Home › Companies › AKERO THERAPEUTICS INC. › 2023-2024

AKERO THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and AKERO THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Ballot items
206Asset managers
1,542Fund votes
June 7, 2024Meeting date

Results at a glance

Meeting of June 7, 2024: 6 items on AKERO THERAPEUTICS INC.’s Form 8-K, filed June 12, 2024: 6 without a stated outcome.

Material dissent

Elect Director: Seth L. Harrison, M.D. 30% of votes cast Outcome not stated Director under 80%
Elect Director: Graham Walmsley, M.D., Ph.D. 64% of votes cast Outcome not stated Director under 80%
Elect Director: Yuan Xu, Ph.D. 32% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AKERO THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by AKERO THERAPEUTICS INC.

These tallies are AKERO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AKERO THERAPEUTICS INC. — official shareholder meeting results, meeting held June 7, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Seth L. Harrison, M.D.	16,924,611	--	--	38,742,993	3,920,264	30%	Not verified	—
Elect Director: Graham Walmsley, M.D., Ph.D.	35,755,718	--	--	19,911,886	3,920,264	64%	Not verified	—
Elect Director: Yuan Xu, Ph.D.	18,067,658	--	--	37,599,946	3,920,264	32%	Not verified	—
The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.	59,238,349	37,608	311,911	--	0	99.9%	Not verified	—
The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.	52,835,974	2,548,327	283,303	--	3,920,264	95%	Not verified	—
The Company's stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation in Proposal 4.	51,521,703	3,864,198	281,703	--	3,920,264	93%	Not verified	—

Source: AKERO THERAPEUTICS INC., Form 8-K, filed with the SEC on June 12, 2024 — read the filing on EDGAR.

How asset managers voted at the AKERO THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 206 asset managers that disclosed a AKERO THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Graham Walmsley, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%WITHHELD

FOR: 35,755,718WITHHELD: 19,911,886

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Graham Walmsley, M.D., Ph.D

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Graham Walmsley, M.D., Ph.D.”): 35,755,718 for, 19,911,886 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 13,737,745 for, 9,486,537 withheld, 284,190 abstained.

FORWITHHOLD

FOR: 13,737,745ABSTAIN: 284,190WITHHOLD: 9,486,537

Largest asset managers voting on “Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her suc” at AKERO THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	5,046,325	0	12,400	For
T. Rowe Price	0	0	3,875,162	Withhold
BlackRock	2,380,119	0	0	For
State Street	2,290,422	0	33,646	For
JANUS INVESTMENT FUND	191,879	0	1,911,454	Mixed
Fidelity	1,359,256	0	26,604	For
AllianceBernstein	0	0	521,101	Withhold
Charles Schwab	518,559	0	0	For
Hartford	489,288	0	0	For
Advantage Advisers Xanthus Fund, L.L.C.	0	0	460,936	Withhold
ALGER INSTITUTIONAL FUNDS	0	0	335,729	Withhold
AB DISCOVERY GROWTH FUND, INC.	0	0	299,867	Withhold
ALGER FUNDS II	0	0	285,489	Withhold
Principal	152	0	279,402	Withhold
Equitable	94,715	0	184,134	Mixed
ALGER FUNDS	0	0	265,096	Withhold
Direxion Shares ETF Trust	0	0	240,720	Withhold
FINANCIAL INVESTORS TRUST	0	224,829	0	Abstain
JPMorgan	223,094	0	0	For
Aberdeen	0	0	199,237	Withhold
Artisan	191,790	0	0	For
John Hancock	98,556	53,043	0	Mixed
TIAA	143,324	0	0	For
QUANTITATIVE MASTER SERIES LLC	114,702	0	0	For
Northwestern Mutual	96,068	0	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

2. Elect Director: Seth L. Harrison, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

30% Plurality election · of votes cast

FOR 30%WITHHELD

FOR: 16,924,611WITHHELD: 38,742,993

Details: description as filed, official tally, votes by 66 asset managers

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Seth L. Harrison, M.D.”): 16,924,611 for, 38,742,993 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 30% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 3,720,180 for, 19,097,539 withheld, 690,753 abstained.

FORWITHHOLD

FOR: 3,720,180ABSTAIN: 690,753WITHHOLD: 19,097,539

Largest asset managers voting on “Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her suc” at AKERO THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,503,290	0	1,555,435	Mixed
T. Rowe Price	0	0	3,875,162	Withhold
BlackRock	0	0	2,380,119	Withhold
State Street	25,011	0	2,299,057	Withhold
JANUS INVESTMENT FUND	191,879	0	1,911,454	Mixed
Fidelity	0	0	1,385,860	Withhold
AllianceBernstein	0	0	521,101	Withhold
Charles Schwab	0	0	518,559	Withhold
Hartford	0	0	489,288	Withhold
Advantage Advisers Xanthus Fund, L.L.C.	0	0	460,936	Withhold
ALGER INSTITUTIONAL FUNDS	0	0	335,729	Withhold
AB DISCOVERY GROWTH FUND, INC.	0	0	299,867	Withhold
ALGER FUNDS II	0	0	285,489	Withhold
Principal	0	0	279,554	Withhold
Equitable	0	0	278,849	Withhold
ALGER FUNDS	0	0	265,096	Withhold
Direxion Shares ETF Trust	0	0	240,720	Withhold
FINANCIAL INVESTORS TRUST	0	224,829	0	Abstain
JPMorgan	0	223,094	0	Abstain
Aberdeen	0	0	199,237	Withhold
Artisan	0	0	191,790	Withhold
John Hancock	0	151,599	0	Abstain
TIAA	0	0	143,324	Withhold
QUANTITATIVE MASTER SERIES LLC	0	0	114,702	Withhold
Northwestern Mutual	0	0	96,068	Withhold

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

3. Elect Director: Yuan Xu, Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

32% Plurality election · of votes cast

FOR 32%WITHHELD

FOR: 18,067,658WITHHELD: 37,599,946

Details: description as filed, official tally, votes by 66 asset managers

AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Yuan Xu, Ph.D.”): 18,067,658 for, 37,599,946 withheld, per its Form 8-K filed June 12, 2024 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 32% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 4,251,946 for, 18,841,706 withheld, 414,820 abstained.

FORWITHHOLD

FOR: 4,251,946ABSTAIN: 414,820WITHHOLD: 18,841,706

Largest asset managers voting on “Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her suc” at AKERO THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,503,290	0	1,555,435	Mixed
T. Rowe Price	0	0	3,875,162	Withhold
BlackRock	0	0	2,380,119	Withhold
State Street	25,011	0	2,299,057	Withhold
JANUS INVESTMENT FUND	191,879	0	1,911,454	Mixed
Fidelity	7,281	0	1,378,579	Withhold
AllianceBernstein	0	0	521,101	Withhold
Charles Schwab	0	0	518,559	Withhold
Hartford	0	0	489,288	Withhold
Advantage Advisers Xanthus Fund, L.L.C.	0	0	460,936	Withhold
ALGER INSTITUTIONAL FUNDS	0	0	335,729	Withhold
AB DISCOVERY GROWTH FUND, INC.	0	0	299,867	Withhold
ALGER FUNDS II	0	0	285,489	Withhold
Principal	0	0	279,554	Withhold
Equitable	0	0	278,849	Withhold
ALGER FUNDS	0	0	265,096	Withhold
Direxion Shares ETF Trust	0	0	240,720	Withhold
FINANCIAL INVESTORS TRUST	0	224,829	0	Abstain
JPMorgan	223,094	0	0	For
Aberdeen	0	0	199,237	Withhold
Artisan	191,790	0	0	For
John Hancock	0	151,599	0	Abstain
TIAA	0	0	143,324	Withhold
QUANTITATIVE MASTER SERIES LLC	0	0	114,702	Withhold
Northwestern Mutual	0	0	96,068	Withhold

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

4. The Company's stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation in…

Outcome not verifiedSHAREHOLDER RIGHTS AND DEFENSESReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 51,521,703AGAINST: 3,864,198

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, TO LIMIT THE LIABILITY OF CERTAIN OFFICERS OF AKERO THERAPEUTICS, INC., AS PERMITTED BY RECENT AMENDMENTS TO DELAWARE LAW.

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation in Proposal 4.”): 51,521,703 for, 3,864,198 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 23,165,468 for, 332,802 against, 10,202 abstained.

FOR

FOR: 23,165,468AGAINST: 332,802ABSTAIN: 10,202

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, TO LIMIT THE LIABILIT” at AKERO THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	5,058,725	0	For
T. Rowe Price	3,875,162	0	For
BlackRock	2,380,119	0	For
State Street	2,320,095	3,973	For
JANUS INVESTMENT FUND	2,103,333	0	For
Fidelity	1,385,860	0	For
AllianceBernstein	521,101	0	For
Charles Schwab	518,559	0	For
Hartford	489,288	0	For
Advantage Advisers Xanthus Fund, L.L.C.	460,936	0	For
ALGER INSTITUTIONAL FUNDS	335,729	0	For
AB DISCOVERY GROWTH FUND, INC.	299,867	0	For
ALGER FUNDS II	285,489	0	For
Principal	279,554	0	For
Equitable	278,849	0	For
ALGER FUNDS	265,096	0	For
Direxion Shares ETF Trust	240,720	0	For
FINANCIAL INVESTORS TRUST	224,829	0	For
JPMorgan	0	223,094	Against
Aberdeen	199,237	0	For
Artisan	191,790	0	For
John Hancock	151,599	0	For
TIAA	143,324	0	For
QUANTITATIVE MASTER SERIES LLC	114,702	0	For
Northwestern Mutual	96,068	0	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

5. The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 10 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 52,835,974AGAINST: 2,548,327

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive officers.

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.”): 52,835,974 for, 2,548,327 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 67 asset managers voting on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive offi” at AKERO THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Withheld	Vote
Vanguard	5,058,725	0	0	For
T. Rowe Price	3,875,162	0	0	For
BlackRock	2,380,119	0	0	For
State Street	2,318,533	5,535	0	For
JANUS INVESTMENT FUND	2,103,333	0	0	For
Fidelity	1,385,860	0	0	For
AllianceBernstein	521,101	0	0	For
Charles Schwab	518,559	0	0	For
Hartford	489,288	0	0	For
Advantage Advisers Xanthus Fund, L.L.C.	460,936	0	0	For
Artisan	435,859	0	0	For
ALGER INSTITUTIONAL FUNDS	0	335,729	0	Against
AB DISCOVERY GROWTH FUND, INC.	299,867	0	0	For
ALGER FUNDS II	0	285,489	0	Against
Principal	279,554	0	0	For
Equitable	278,849	0	0	For
ALGER FUNDS	0	265,096	0	Against
Simplify Exchange Traded Funds	0	0	263,354	Withhold
Direxion Shares ETF Trust	240,720	0	0	For
FINANCIAL INVESTORS TRUST	224,829	0	0	For
JPMorgan	223,094	0	0	For
Aberdeen	0	199,237	0	Against
John Hancock	151,599	0	0	For
TIAA	143,324	0	0	For
QUANTITATIVE MASTER SERIES LLC	114,702	0	0	For

Fund voting reports, all 67 managers: 22,551,509 for, 1,190,830 against, 263,354 withheld, 10,202 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 156 asset managers voting on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive offi” at AKERO THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Janus Henderson	6,170,609	0	For
GENERAL ATLANTIC, L.P.	5,233,989	0	For
T. Rowe Price	5,105,551	0	For
Wellington	4,356,260	0	For
State Street	3,435,370	5,610	For
RTW INVESTMENTS, LP	3,258,609	0	For
BlackRock	1,912,395	16,619	For
Redmile Group, LLC	1,858,702	0	For
Boxer Capital, LLC	1,676,733	0	For
AllianceBernstein	1,445,179	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,414,136	0	For
Rock Springs Capital Management LP	1,299,888	0	For
FRED ALGER MANAGEMENT, LLC	59,703	1,199,976	Against
Yiheng Capital Management, L.P.	1,145,144	0	For
ALKEON CAPITAL MANAGEMENT LLC	1,072,051	0	For
Logos Global Management LP	800,000	0	For
Charles Schwab	535,310	0	For
Northern Trust	488,865	54	For
EMERALD MUTUAL FUND ADVISERS TRUST	424,901	0	For
MPM BioImpact LLC	337,555	0	For
EMERALD ADVISERS, LLC	302,273	0	For
JPMorgan	278,997	0	For
Point72	278,048	0	For
Ensign Peak Advisors, Inc	268,491	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	261,886	0	For

Institutional-manager reports, all 156 managers: 45,227,819 for, 1,935,963 against, 15,012 not voted. Showing the 25 largest; see all in the interactive database.

6. The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 59,238,349AGAINST: 37,608

Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.”): 59,238,349 for, 37,608 against, per its Form 8-K filed June 12, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 23,498,270 for, 10,202 abstained.

FOR

FOR: 23,498,270ABSTAIN: 10,202

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR TH” at AKERO THERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	5,058,725	For
T. Rowe Price	3,875,162	For
BlackRock	2,380,119	For
State Street	2,324,068	For
JANUS INVESTMENT FUND	2,103,333	For
Fidelity	1,385,860	For
AllianceBernstein	521,101	For
Charles Schwab	518,559	For
Hartford	489,288	For
Advantage Advisers Xanthus Fund, L.L.C.	460,936	For
ALGER INSTITUTIONAL FUNDS	335,729	For
AB DISCOVERY GROWTH FUND, INC.	299,867	For
ALGER FUNDS II	285,489	For
Principal	279,554	For
Equitable	278,849	For
ALGER FUNDS	265,096	For
Direxion Shares ETF Trust	240,720	For
FINANCIAL INVESTORS TRUST	224,829	For
JPMorgan	223,094	For
Aberdeen	199,237	For
Artisan	191,790	For
John Hancock	151,599	For
TIAA	143,324	For
QUANTITATIVE MASTER SERIES LLC	114,702	For
Northwestern Mutual	96,068	For

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Largest AKERO THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.

Fund voting reports: top AKERO THERAPEUTICS INC. shareholders by shares voted on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named…”, 2023-2024
#	Asset manager	Shares voted
1	Vanguard	5,058,725
2	T. Rowe Price	3,875,162
3	BlackRock	2,380,119
4	State Street	2,324,068
5	JANUS INVESTMENT FUND	2,103,333
6	Fidelity	1,385,860
7	AllianceBernstein	521,101
8	Charles Schwab	518,559
9	Hartford	489,288
10	Advantage Advisers Xanthus Fund, L.L.C.	460,936

Institutional-manager reports: top AKERO THERAPEUTICS INC. shareholders by shares voted on “To consider and act upon a non- binding, advisory vote to approve the compensation of our named…”, 2023-2024
#	Asset manager	Shares voted
1	Janus Henderson	6,170,609
2	GENERAL ATLANTIC, L.P.	5,233,989
3	T. Rowe Price	5,105,551
4	Wellington	4,356,260
5	State Street	3,440,980
6	RTW INVESTMENTS, LP	3,258,609
7	BlackRock	1,929,014
8	Redmile Group, LLC	1,858,702
9	Boxer Capital, LLC	1,676,733
10	AllianceBernstein	1,445,179

Shown as share counts, not percentages: no shares-outstanding figure has been matched to AKERO THERAPEUTICS INC. for the 2023-2024 season, so there is no denominator to divide by.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At AKERO THERAPEUTICS INC.'s shareholder meeting held June 7, 2024, in the 2023-2024 proxy season, 206 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,542 separate fund positions. On the most widely held item on that ballot — To consider and act upon a non- binding, advisory vote to approve the compensation of our named… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AKERO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2024.

AKERO THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.